I was first drawn to medicine because I wanted to help people. I chose hematology and oncology because they are rapidly evolving fields—through their advances, I can treat people using the newest therapies. More importantly, I can care for people by forging meaningful relationships with them.
I treat each patient as a partner, and together, we work toward a common goal. Communication with my patients and their caregivers is essential to providing the best care. I also prioritize providing my patients with access to clinical trials.
At Perlmutter Cancer Center, my colleagues and I approach cancer treatment as a collaboration between specialties. We offer patients the most current clinical trials and we strive to provide as much support as possible for patients and families during such a difficult time.
My clinical and research interest is gastrointestinal cancers, with a focus on liver and biliary cancer, pancreatic cancer, and gastric cancer. Currently, I am studying whether radiation therapy in combination with immunotherapy is an effective treatment for pancreatic cancer.
Conditions and Treatments
- abdominal tumor
- anal cancer
- biliary cancer
- colon cancer
- colorectal cancer
- esophageal cancer
- gallbladder cancer
- gastrointestinal cancer
- liver cancer
- pancreatic cancer
- rectal cancer
- stomach cancer
- Associate Professor, Department of Medicine at NYU Grossman School of Medicine
- Director, Bellevue Cancer Center
- Section Chief, Hematology and Medical Oncology, Bellevue Hospital
- American Board of Internal Medicine (Hematology), 2007
- American Board of Internal Medicine (Medical Oncology), 2006
- American Board of Internal Medicine - Internal Medicine, 2003
Education and Training
- Fellowship, NYU Medical Center, Hematology/Oncology, 2006
- Fellowship, NYU Medical Center, Hematology/Oncology, 2004
- MD from Albert Einstein College of Med, 2000
Is this your profile?Edit profile
Insurance Plans Accepted
This provider accepts the following insurance plans.
- Emblem Select Care Exchange
- GHI HMO
- Hotel Trades
- Railroad Medicare
Senior Whole Health
- Senior Whole Health
- WellCare Medicare
Clinical Trials and Research Studies
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence.
A Phase II study of Atezolizumab and Bevacizumab in Child-Pugh B7 Hepatocellular Carcinoma.
Phase II Trial of Radium-223 Dichloride in Combination with Paclitaxel in Patients with Bone Metastatic Breast Cancer
N<sup>6</sup>-Methyladenosine Modification of ANLN Enhances Hepatocellular Carcinoma Bone Metastasis
International journal of biological sciences. 2023 Mar ; 19(4):1009-1023
World journal of gastroenterology : WJG. 2022 Jun 21; 28(23):2561-2568
Prescreening to Increase Therapeutic Oncology Trial Enrollment at the Largest Public Hospital in the United States
JCO oncology practice. 2021 Nov 08; OP2100629